Molecular Partners AG ADR
$ 4.11
10.78%
12 Jun - close price
- Market Cap 154,171,000 USD
- Current Price $ 4.11
- High / Low $ 4.11 / 4.11
- Stock P/E N/A
- Book Value 2.33
- EPS -1.94
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.59 %
- 52 Week High 5.36
- 52 Week Low 3.41
About
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland.
Analyst Target Price
$10.96
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-12 | 2025-10-30 | 2025-08-25 | 2025-05-15 | 2025-03-06 | 2024-10-31 | 2024-08-26 | 2024-05-16 | 2024-03-14 | 2023-10-26 | 2023-08-23 |
| Reported EPS | -0.4472 | -0.36 | -0.4021 | -0.6867 | -0.45 | -0.3 | -0.5629 | -0.46 | -0.6 | -0.6 | -0.3943 | -0.5417 |
| Estimated EPS | -0.4135 | -0.388 | -0.4795 | -0.4995 | -0.37 | -0.39 | -0.6288 | -1.26 | -1 | -0.97 | 0 | -0.87 |
| Surprise | -0.0337 | 0.028 | 0.0774 | -0.1872 | -0.08 | 0.09 | 0.0659 | 0.8 | 0.4 | 0.37 | -0.3943 | 0.3283 |
| Surprise Percentage | -8.1499% | 7.2165% | 16.1418% | -37.4775% | -21.6216% | 23.0769% | 10.4803% | 63.4921% | 40% | 38.1443% | None% | 37.7356% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MOLN
2026-06-01 11:09:09
Molecular Partners (MOLN) announced its lead targeted alpha radiotherapy candidate, MP0712, is now dosing patients in a Phase 1/2a study for small cell lung cancer and other DLL3-expressing tumors. The company will present trial-in-progress posters at the 2026 ASCO and SNMMI annual meetings, and anticipates sharing initial clinical data from this study in 2026. MP0712, co-developed with Orano Med, targets DLL3 which is highly expressed in over 85% of SCLC tumors.
2026-05-30 12:10:00
Molecular Partners AG announced it will present trial-in-progress posters for its Phase 1/2a study of MP0712, a targeted alpha radiotherapy candidate, at the 2026 ASCO and SNMMI Annual Meetings. MP0712 targets the DLL3 protein in small cell lung cancer and other neuroendocrine tumors, with initial clinical data expected later this year. The company is collaborating with Orano Med on this Radio-DARPin platform drug, which aims to evaluate safety and determine a recommended Phase 2 dose.
2026-05-30 12:09:10
Molecular Partners (NASDAQ: MOLN) announced that its DLL3-targeting radio-DARPin MP0712 is now dosing patients in a US Phase 1/2a trial for small cell lung cancer and other neuroendocrine tumors. The company will present trial-in-progress posters at ASCO 2026 and SNMMI 2026, with initial clinical data expected in 2026. This therapy relies on the high expression of DLL3 in over 85% of SCLC tumors and leverages a diagnostic isotope, 203Pb, for early imaging and dosimetry data, supporting its continued clinical development.
2026-05-29 06:40:56
Molecular Partners announced it will present trial-in-progress poster presentations at the ASCO and SNMMI 2026 annual meetings regarding its lead targeted alpha radiotherapy candidate, MP0712. MP0712, a 212Pb-based Radio-DARPin Therapy targeting DLL3 for small cell lung cancer and neuroendocrine cancers, is currently dosing patients in a Phase 1/2a study. The company anticipates sharing initial clinical data from this study later in 2026, following promising preliminary imaging and dosimetry data presented earlier in the year.
2026-05-26 19:39:35
Molecular Partners (NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, announced its participation in TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30 AM ET. Management will engage in a fireside chat, which will be webcast live on the company's website. The event provides an opportunity for investors to learn about the company's clinical progress, cash runway, and upcoming milestones for its oncology pipeline, including MP0712 and MP0317.
2026-05-13 19:10:33
Molecular Partners AG's average 12-month price target has been increased from $9.95 to $10.31 by 8 analysts, suggesting a potential upside of 155% from its May 12 closing price. The consensus rating for the stock remains "Buy," with 6 analysts recommending Buy and 2 recommending Hold.
